Aripiprazole

DEA Class;  Rx

Common Brand Names; Abilify, Abilify Maintena, Abilify MyCite, Aristada, Aristada Initio

Hypersensitivity to aripiprazole

Weight gain (8-30%)

Headache (27%)

Agitation (19%)

Insomnia (18%)

Anxiety (17%)

Nausea and vomiting (11-15%)

Akathisia (10-13%)

Lightheadedness (11%)

Constipation (10-11%)

1-10%

Dizziness (10%)

Dyspepsia (9%)

Somnolence (5-8%)

Fatigue (6%)

Restlessness (6%)

Tremor (6%)

Dry mouth/xerostomia (5%)

Extrapyramidal disorder (5%)

Orthostatic hypotension (1-5%)

Musculoskeletal stiffness (4%)

Abdominal discomfort (3%)

Blurred vision (3%)

Cough (3%)

Pain (3%)

Myalgia (2%)

Rash

Rhinitis

Aripiprazole lauroxil

• Extrapyramidal symptoms (5-7%)
• Injection site reactions (4%)
• Pain at injection site (<2%)
• Increased weight (<2%)
• Increased creatinine phosphokinase (<2%)
• Akathisia (<2%)
• Headache (<2%)
• Insomnia (<2%)
• Restlessness (<2%)

Risk of extrapyramidal symptoms (EPS) (eg, pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia; monitor

Tardive dyskinesia may occur; may consider discontinuation of therapy if clinically indicated

Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity and/or autonomic instability

May cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries; perform complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy

Use caution in patients with known cardiovascular disease, cerebrovascular disease, or predisposition to hypotension; may increase incidence of cerebrovascular adverse reactions (eg, stroke, transient ischemic attack, including fatalities)

Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope

Use caution in patients with Parkinson disease; may aggravate motor disturbances

May increase risk of suicidal tendencies in children and adolescents (see Black Box Warnings)

FDA warning regarding off-label use for dementia in elderly (see Black Box Warnings)

Patients may act on dangerous impulses (eg, gambling)

Monitor for orthostatic hypotension

May cause seizures or convulsions; use cautiously in patients with history of seizures or with conditions that lower the seizure threshold

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ARISTADA during pregnancy

Aripiprazole is present in human breast milk; there are reports of poor weight gain in breastfed infants exposed to aripiprazole and reports of inadequate milk supply in lactating women taking aripiprazole; development and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from treatment or from underlying maternal condition